NASDAQ:KTTA Pasithea Therapeutics (KTTA) Stock Price, News & Analysis $0.52 +0.00 (+0.40%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$0.49 -0.04 (-6.70%) As of 11/13/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Pasithea Therapeutics Stock (NASDAQ:KTTA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pasithea Therapeutics alerts:Sign Up Key Stats Today's Range$0.46▼$0.5850-Day Range$0.37▼$0.6052-Week Range$0.28▼$2.06Volume2.36 million shsAverage Volume1.59 million shsMarket Capitalization$17.44 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company Overview Pasithea Therapeutics is a clinical-stage biotechnology company developing therapies for serious diseases. Its current focus is PAS-004, a next-generation macrocyclic MEK inhibitor being studied for conditions associated with the RAS/MAPK signaling pathway, including neurofibromatosis type 1. The company’s research has shifted over time: Pasithea previously focused on treatments for neurological and psychiatric disorders. Its current development efforts are centered on PAS-004 and potential applications in diseases with limited treatment options. Pasithea is headquartered in the United States and is listed on the Nasdaq under the ticker KTTA.AI Generated. May Contain Errors. Read More Pasithea Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreKTTA MarketRank™: 2.858642866515 of 5 starsPasithea Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 432nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingPasithea Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialPasithea Therapeutics has a consensus price target of $3.00, representing about 474.7% upside from its current price of $0.52.Amount of Analyst CoveragePasithea Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Pasithea Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pasithea Therapeutics are expected to grow in the coming year, from ($0.76) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pasithea Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pasithea Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPasithea Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.17% of the float of Pasithea Therapeutics has been sold short.Short Interest Ratio / Days to CoverPasithea Therapeutics has a short interest ratio ("days to cover") of 0.84, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pasithea Therapeutics has recently increased by 121.49%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPasithea Therapeutics does not currently pay a dividend.Dividend GrowthPasithea Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.64 News SentimentPasithea Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Pasithea Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Pasithea Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.50% of the stock of Pasithea Therapeutics is held by insiders.Percentage Held by Institutions23.92% of the stock of Pasithea Therapeutics is held by institutions.Read more about Pasithea Therapeutics' insider trading history. Receive KTTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KTTA Stock News HeadlinesPasithea Reports Tumor Shrinkage With PAS-004 In Neurofibromatosis Trial; Stock UpNovember 13 at 6:39 PM | rttnews.comPasithea oral drug shrank NF1 skin tumors in all 15 evaluable patients; no placebo groupNovember 13 at 1:37 PM | msn.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 15 at 1:00 AM | Weiss Ratings (Ad)Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform ...November 13 at 8:37 AM | finance.yahoo.comPasithea Therapeutics Reports Positive PAS-004 Clinical Data in NF1-Associated Neurofibromas and FDA Clearance for Phase 2 cNF TrialNovember 13 at 2:11 AM | quiverquant.comQPasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis ConferenceNovember 13 at 2:00 AM | globenewswire.comPasithea Therapeutics (KTTA) Set to Announce Quarterly Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comPasithea Therapeutics (NASDAQ:KTTA) Stock Crosses Above Fifty Day Moving Average - Here's WhyNovember 4, 2026 | americanbankingnews.comSee More Headlines KTTA Stock Analysis - Frequently Asked Questions How have KTTA shares performed this year? Pasithea Therapeutics' stock was trading at $1.29 at the start of the year. Since then, KTTA shares have decreased by 59.5% and is now trading at $0.5220. How were Pasithea Therapeutics' earnings last quarter? Pasithea Therapeutics Corp. (NASDAQ:KTTA) posted its quarterly earnings data on Friday, November, 13th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. When did Pasithea Therapeutics' stock split? Shares of Pasithea Therapeutics reverse split on Tuesday, January 2nd 2024.The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Pasithea Therapeutics IPO? Pasithea Therapeutics (KTTA) raised $17 million in an initial public offering on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share. How do I buy shares of Pasithea Therapeutics? Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pasithea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Plug Power (PLUG), Advanced Micro Devices (AMD), Can-Fite BioPharma (CANF) and Ginkgo Bioworks (DNA). Company Calendar Last Earnings11/13/2026Today11/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 KTTA's financial health is in the Red zone, according to TradeSmith. KTTA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KTTA CIK1841330 Webwww.pasithea.com Phone702-514-4174FaxN/AEmployees5Year Founded2020Price Target and Rating Average Price Target for Pasithea Therapeutics$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside+474.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.49% Return on Assets-46.81% Debt Debt-to-Equity RatioN/A Current Ratio26.25 Quick Ratio26.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book0.22Miscellaneous Outstanding Shares33,410,000Free Float32,913,000Market Cap$17.44 million OptionableNot Optionable Beta0.39 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:KTTA) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.